Ginkgo Bioworks Holdings (DNA) Change in Accured Expenses (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has reported Change in Accured Expenses for 7 consecutive years, with $3.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Accured Expenses rose 132.3% year-over-year to $3.9 million; the trailing twelve-month figure through Jun 2026 stood at $6.1 million (up 111.09% YoY), and the FY2025 full-year result was $10.4 million, up 125.66% from the prior year.
• Change in Accured Expenses rose to $3.9 million in Q2 2026 per DNA's latest filing, from -$11.6 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $21.7 million in Q4 2023 and bottomed at -$42.0 million in Q3 2024.
• Historically, Change in Accured Expenses has averaged -$3.4 million across 5 years, with a median of -$412500.0 in 2023.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses jumped 178.17% in 2023, then tumbled 174328.57% in 2025.
• Over 5 years, Change in Accured Expenses stood at -$27.8 million in 2022, then soared by 178.17% to $21.7 million in 2023, then tumbled by 143.0% to -$9.3 million in 2024, then advanced by 29.17% to -$6.6 million in 2025, then soared by 159.62% to $3.9 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $3.9 million, -$11.6 million, and -$6.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.